<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002203</url>
  </required_header>
  <id_info>
    <org_study_id>280A</org_study_id>
    <secondary_id>NZTA4001</secondary_id>
    <nct_id>NCT00002203</nct_id>
  </id_info>
  <brief_title>A Study of Two Anti-HIV Drug Combinations</brief_title>
  <official_title>A Randomized, Multicenter Study of Epivir 150 Mg Bid, Retrovir 200 Mg Tid and a Protease Inhibitor Vs 3TC 150 Mg/ZDV 300 Mg Fixed Dose Tablet Given Bid With a Protease Inhibitor in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of taking lamivudine&#xD;
      (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV&#xD;
      combination tablet (Combivir) plus a PI. This study also examines how well patients follow&#xD;
      the dosing schedules for these drugs.&#xD;
&#xD;
      Doctors believe that taking Combivir plus a PI may be as effective as taking 3TC plus ZDV&#xD;
      plus a PI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is hypothesized that a fixed-dose 3TC/ZDV tablet given bid in combination with a protease&#xD;
      inhibitor is clinically equivalent in its effect on plasma HIV-1 RNA level to a conventional&#xD;
      regimen of 3TC, ZDV, and a protease inhibitor.&#xD;
&#xD;
      Patients are stratified according to their current protease inhibitor therapy and randomized&#xD;
      to receive open-label therapy of 1 Combivir tablet bid (Arm II) or an equivalent dose of 3TC&#xD;
      and ZDV (Arm I), plus their current protease inhibitor for 16 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine/Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection documented by a licensed antibody ELISA assay and confirmed by Western&#xD;
             blot, positive HIV blood culture, positive HIV serum antigen, or plasma viremia.&#xD;
&#xD;
          -  CD4+ cell count of at least 300 cells/mm3.&#xD;
&#xD;
          -  HIV-1 RNA less than 10,000 copies/ml by Roche Amplicor PCR assay.&#xD;
&#xD;
          -  CDC Category A or B Classification for HIV infection (no clinical diagnosis of AIDS).&#xD;
&#xD;
          -  Compliance with dosing schedule and protocol evaluations.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  3TC at 150 mg bid, ZDV at 600 mg/day (200 mg tid or 300 mg bid), plus a marketed&#xD;
             protease inhibitor (ritonavir, saquinavir, indinavir, or nelfinavir) at its&#xD;
             recommended dose for at least 10 weeks.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Inhaled corticosteroids for the treatment of asthma.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Malabsorption syndromes affecting drug absorption (e.g., Crohn's disease and chronic&#xD;
             pancreatitis).&#xD;
&#xD;
          -  Enrollment in other investigational protocols.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Cytotoxic chemotherapeutic agents.&#xD;
&#xD;
          -  Nonnucleoside reverse transcriptase inhibitors.&#xD;
&#xD;
          -  Other investigational agents.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Radiation therapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Cytotoxic chemotherapeutic and immunomodulating agents such as systemic&#xD;
             corticosteroids, IF-2, alpha-IFN, beta-IFN, or gamma-IFN (except for inhaled&#xD;
             corticosteroids for the treatment of asthma) within 4 weeks of study entry.&#xD;
&#xD;
          -  HIV immunotherapeutic vaccine within 3 months of study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Radiation therapy within 4 weeks of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pacific Oaks Med Ctr</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tower Infectious Diseases / Med Associates Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina Hosps</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Med Ctr</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Physicians Inc</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Wisconsin School of Medicine</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan AIDS Program</name>
      <address>
        <city>Santurce</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1998</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>CD4 Lymphocyte Count</keyword>
  <keyword>CD4-CD8 Ratio</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Patient Compliance</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

